linjc16/ctgov huggingface dataset:
ASYMMETRIC LACK OF KNEE FLEXION AS A SYMPTOM OF DLM IN CHILDREN

Study Overview
=================
Brief Summary
-----------------
Highlighted during the clinical examination of a knee flexion asymmetry, and related to the intraoperative meniscal observations on DLM. Search for a link between asymmetric bending defect and posterior shift in MCA-type DLM. Analysis of all patients with symptomatic DLM.

Official Title
-----------------
ASYMMETRIC LACK OF KNEE FLEXION AS A SYMPTOM OF DLM IN CHILDREN

Conditions
-----------------
Highlights a New Clinical Sign Which Point Out a Meniscus Posterior Luxation Because of a MCA-type DLM

Intervention / Treatment
-----------------
* Diagnostic Test: Find a link between lack of knee flexion and meniscal posterior luxation fixed


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: < 18 yo Symptomatic discoid lateral meniscus Exclusion Criteria: Osteochondritis dissecans (OCD) Asymptomatic and partial DLM observed during arthroscopic exploration for other reasons Revision knee surgery

Ages Eligible for Study
-----------------
Minimum Age: 0 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lack of knee flexion<br>During preoperative clinical exam, highlight of a lack of knee flexion. The lack of knee flexion consists in an asymmetric heel-bottom distance or an asymmetric goniometric measure of knee flexion. All others characteristics are also analyzed like in group 2, as : rest of knee motion, MRI meniscus shift, arthroscopic shift | Diagnostic Test: Find a link between lack of knee flexion and meniscal posterior luxation fixed<br>* Measure the full flexion angle of the knee using a goniometer. Measure the heel-buttom distance. All measurements are carried out in bilateral and comparative ways. Search for the meniscal position on MRI and intraoperatively: no shift, anterior, medial, posterior shift.<br>|
| Full knee flexion<br>During preoperative clinical exam, highlight of a lack of knee flexion. The lack of knee flexion consists in an asymmetric heel-bottom distance or an asymmetric goniometric measure of knee flexion. Patients in group 2 don't have any asymmetric full knee flexion. All others characteristics are also analyzed like in group 2, as : rest of knee motion, MRI meniscus shift, arthroscopic shift | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Meniscal posterior shift per-operative | Visualization of a dislocated posterior meniscus during arthroscopy, before any reduction or meniscoplasty procedure | During surgery for MCA-type DLM | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
discoid lateral meniscus, children, instability, arthroscopy, repair, lack of flexion, flexion block knee
Study on the Relationship Between Periodontitis and Renal Disease

Study Overview
=================
Brief Summary
-----------------
Analysis of inflammatory markers in periodontitis and patients with early and middle stage renal disease.

Detailed Description
-----------------
A total of 200 population is recruited, individuals are divided into four groups according to a periodontal examination and a general physical examination: healthy individuals ,periodontitis, renal disease patients with healthy periodontium, and renal disease patients wth peridontitis. Fasting blood samples and gingival crevicular fluid are collected from all individuals, and inflammatory markers are analysed for the four groups.

Official Title
-----------------
Affiliated Hospital of Stomatology, School of Medicine, Zhejiang University

Conditions
-----------------
Periodontitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all participants were in general good health(except renal disease) and non-smoking Exclusion Criteria: less than 20 teeth in the dentin hypertension the presence of systemic disease (e.g., diabetes mellitus ,coronary heart disease, liver, or lung disease) a history or the symptom of any other acute or chronic infections systemic antibiotic treatment within previous 4 weeks periodontal treatment within1 month

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group A<br>the control group,healthy individuals | |
| Group B<br>patients with 1-4 stage K/DOQI (Kidney Disease Outcome Quality Initiative) chronic kidney disease, but healthy periodontium | |
| Group C<br>patients with periodontitis, but healthy renal conditions | |
| Group D<br>patients with 1-4 stage K/DOQI (Kidney Disease Outcome Quality Initiative) chronic kidney disease and periodontitis | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inflammatory markers analysis of the four groups | Analysis of inflammatory biomarkers of blood and gingival crevicular fluid samples of the four groups | 3 months after sampling | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
biomarkers, renal disease, periodontitis
Observational Study of Safety of Flu Cell Culture Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Vaccine

Study Overview
=================
Brief Summary
-----------------
This is an observational study of safety and occurrence of influenza-like illness following administration of flu cell culture derived adjuvanted swine origin A (H1N1) pandemic subunit vaccine in subjects 6 months of age and older.

Official Title
-----------------
A Prospective Observational Study of Safety and Occurrence of Influenza-like Illness Following Administration of Adjuvanted Swine Origin A(H1N1) Pandemic Subunit Vaccine Celtura

Conditions
-----------------
Novel Influenza A (H1N1), A New Flu Virus of Swine Origin

Intervention / Treatment
-----------------
* Other: Non-intervention observational study


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 6 months Subjects will be vaccinated with Flu Cell Culture Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Vaccine, independently of this study. Subjects or parent/guardian willing to provide informed consent prior to vaccination administration and complete all of the study, including follow-up contact Exclusion Criteria: • Received any prior H1N1 vaccination

Ages Eligible for Study
-----------------
Minimum Age: 6 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1: 6-23 months<br> | Other: Non-intervention observational study<br>* Non-intervention observational study<br>|
| Group 2: 2-8 years<br> | Other: Non-intervention observational study<br>* Non-intervention observational study<br>|
| Group 3: 9-17 years<br> | Other: Non-intervention observational study<br>* Non-intervention observational study<br>|
| Group 4: 18-44 years<br> | Other: Non-intervention observational study<br>* Non-intervention observational study<br>|
| Group 5: 45-60 years<br> | Other: Non-intervention observational study<br>* Non-intervention observational study<br>|
| Group: >60 years<br> | Other: Non-intervention observational study<br>* Non-intervention observational study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To quantify the safety of Flu Cell Culture Derived Adjuvanted Swine Origin A(H1N1) Pandemic Subunit Vaccine in actively monitored subjects |  | 6 months | 
| To characterize the incidence of AEs in specific age groups following an active surveillance of vaccinated subjects |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the occurrence of laboratory confirmed H1N1sw and influenza-like illness following vaccination |  | 6 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Swine Flu H1N1 vaccine, Adjuvanted flu cell culture derived
Immediate Implant With Provisionalization

Study Overview
=================
Brief Summary
-----------------
Prospective observational clinical study conducted to evaluate the success of graftless immediate implantation with provisionalizaion

Detailed Description
-----------------
In this study 35 graftless immediately placed implant in smile line loaded by provisional office made restoration, the primary and secondary stability measured and compared in addition to evaluation of pink esthetic score

Official Title
-----------------
Primary Versus Secondary Implant Stability in Relation to Gap Distance of Immediate Implant With Immediate Loading by Provisional Restoration

Conditions
-----------------
Maintain the Esthetic

Intervention / Treatment
-----------------
* Procedure: Tooth guided immediate implant placement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Medical and psychological fitness for minor oral surgery. Age 20-60 years. medium to thick gingival biotype. buccal plate thickness more than (1mm). Exclusion Criteria: Smoking habit. Diabetes mellitus. A systemic disorder that is contraindicated for the minor surgical procedure. Pregnancy or lactation. Any irradiation in head and neck area. Need for bone augmentation procedure. Clinical signs of bruxism or other severe functional disorders. patient with periodontal disease.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patient with non restorable teeth<br>Patient with non restorable teeth located in smile line needs extraction with immediate implantation and immediate provisionalization to improve psychiatric effect of tooth loss | Procedure: Tooth guided immediate implant placement<br>* The technique of implant insertion consisted of a progressive preparation of the implant site using the anatomy of the root of the single rooted teeth to be extracted as a reference and as aid for apical engagement<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Implant primary stability | The stability measured by resonance frequancy analysis device (osstell) | 0 day | 
| Jumping gab | The gab that located between the implant surface and buccal plate | 0 day | 
| Pink esthetic score | Denote the esthetic profile of bone and gingiva | 0 day, before extraction and implant placement | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Implant secondary stability | The stability measured by resonance frequancy analysis device (osstell) | Up to 16 weeks | 
| Ridge reduction | The amount of reduction in buccal profile of the alveolar ridge | Up to 16 weeks | 
| Pink esthetic score | Denote the esthetic profile of bone and gingiva | after implantation By 4 months |
Comparison of GAP-score With Schwab-score

Study Overview
=================
Brief Summary
-----------------
The predictive value of two different score-systems with regard to failure rate following long extent spinal fusion is subject of evaluation.

Detailed Description
-----------------
The multilevel spinal fusion is associated with high rate of failure. This results from insufficient adaptation of the fused spine to the proper individual spinal alignment. In the recent years, comprehensive understanding of spinal alignment and definition of several parameters contributed to develop score systems to evaluate the alignment of the multilevel spinal fusion and to predict failure. In the following study the results of multilevel spinal fusion were evaluated retrospectively according to two scoring systems: GAP-score und Schwab-score. The predictive value of each score system is analyzed by the correlation of the failure rate with its corresponding score value.

Official Title
-----------------
Failure Prediction of Adult Spinal Deformity Surgery Comparing GAP-score With Schwab-score

Conditions
-----------------
Spinal Fusion, Adjacent Segment Degeneration

Intervention / Treatment
-----------------
* Procedure: Spinal Fusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 3 and more fusion levels Exclusion Criteria: Neuromuscular disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Spinal Fusion|Spinal alignment was evaluated according to two different score-systems|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Radiological Evaluation | Pelvic tilt in degree, Pelvic incidence in degree, Sacral slope in degree, Lumbar lordosis in degree, L5-S1 lordosis in degree, Thoracic kyphosis in degree, Sagittal vertical axis in degree, Thoracolumbar kyphosis in degree, Global tilt in degree, Cobb angle in degree | 2 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
GAP-score, Schwab score, Proximal Junctional Failure, Spinal Fusion
Cytomegalovirus Spread and Reactivation in Blood Cells

Study Overview
=================
Brief Summary
-----------------
To investigate the relationship between HCMV and bone marrow progenitor cells to understand whether HCMV is latent in CD34 + bone marrow progenitors and the mechanism by which the virus remains in a latent state.

Detailed Description
-----------------
BACKGROUND: Despite progress in understanding the pathophysiology of human cytomegalovirus (HCMV) infections, its manifestations in the immune compromised host are frequently associated with high morbidity and mortality. In this setting, HCMV disease can develop e.g. following immune suppression as a result of reactivation of latent HCMV acquired earlier in life. The mechanisms leading to establishment of latent infections and their subsequent reactivation are not clear. It is also unknown whether HCMV exists in a latent form with limited viral gene expression or as a persistent infection with normal virus transcription. DESIGN NARRATIVE: The specific aims of the study were to: 1) examine the percentage of HCMV positive donors whose bone marrow progenitors contained HCMV DNA using nested PCR and determine if virus could be rescued from those cells. 2) Analyze the HCMV life cycle in hematopoietic progenitor and stem cells. 3) identify and analyze HCMV gene expression in in vivo infected leukocytes. Bone marrow progenitors containing HCMV DNA detectable by nested PCR were isolated from human donors and used as as source of mRNA to prepare Cdna libraries. 4) Determine if gene(s) expressed in bone marrow progenitors were important in either establishing or maintaining a latent infection or in the lytic cycle of HCMV. Information provided from the above studies yielded information important in planning future approaches for the therapy of HCMV infections. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Blood Disease, Cytomegalovirus Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Product Preference With Systane Compared to Artificial Tears on Frequency of Drop Use

Study Overview
=================
Brief Summary
-----------------
The objective of this study was to evaluate the effect of Systane® compared to marketed artificial tears on the frequency of drop use.

Official Title
-----------------
The Effect of Systane® Compared to Marketed Artificial Tears on Frequency of Drop Use

Conditions
-----------------
Dry Eye

Intervention / Treatment
-----------------
* Other: Systane Lubricant eye drops


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects age 18 (minimum); reported history of dry eye syndrome in both eyes; TFBUT ≤ 7 seconds in at least 1 eye at Visit 1; ≥ 1+ fluorescein staining score in any region in at least 1 eye at Visit 1; desire to use an artificial tear substitute for dry eye symptoms at least 4 times per day at Visit 1 and Visit 2. Exclusion Criteria: Age less than 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Systane Lubricant eye drops|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of drop use and/or desire to use; Drop preference |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Product questionnaire; Symptoms; Corneal and conjunctival staining; Tear film break-up time (TFBUT). |  |  |
Population Pharmacokinetics of Tacrolimus in Nephrotic Syndrome

Study Overview
=================
Brief Summary
-----------------
This study will use a multi-center, prospective design, with a Real World Study model, to include 200 patients with nephrotic syndrome. based on the Population Pharmacokinetics (PPK) model, it will study genotype and clinical factors in patients with nephrotic syndrome, to explore the Pharmacokinetics/ Pharmacodynamics (PK/PD) relationship of Tacrolimus in patients with nephrotic syndrome, and develop an optimal medication regimen.

Official Title
-----------------
Population Pharmacokinetics of Tacrolimus for Optimal Dose in Patients With Nephrotic Syndrome

Conditions
-----------------
Nephrotic Syndrome, Tacrolimus, Pharmacokinetics

Intervention / Treatment
-----------------
* Drug: Tacrolimus


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: （1）Patients with Nephrotic Syndrome： Proteinuria greater than 3.5 g/24 hour Serum albumin <30 g/l Clinical evidence of peripheral oedema Hyperlipidemia 1) and 2) are necessary for diagnosis. （2）18-75years old（include 75），gender is not limited； （3）Voluntary signing informed consent。 Exclusion Criteria: （1）Secondary nephrotic syndrome； （2）Allergic to Tacrolimus or other unsuitable use of Tacrolimus； （3）With other immunosuppressive agents such as cyclosporin A, cyclophosphamide, mycophenolate mofetil, leflunomide, tripterygium wilfordii (hormone is not restricted)； （4）Severe liver dysfunction (transaminase > 3 ULN, or bilirubin > 3 ULN)； （5）Severe renal insufficiency（eGFR<30 ml/min/1.73m2） （6）Joined other clinical trials within 1 month； （7）Missing clinical data； （8）Pregnancy, lactation or planning for pregnancy within 12 months； （9）Researchers believe that patients who are not suitable for this clinical trial。

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Tacrolimus|Tacrolimus, oral, 0.05-0.075 mg/kg/d, Q12h, 6～12 months|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change of plasma concentration of Tacrolimus | Study the plasma concentration of Tacrolimus in patients with nephrotic syndrome | at 0hour，2hours，4hours，6hours，9hours，12hours after oral administration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Genotypes as measured by next generation sequencing | Genotypes as measured by next generation sequencing | one week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nephrotic Syndrome, Tacrolimus, Population Pharmacokinetics